Spectral Medical Provides December Tigris Trial Update
MWN-AI** Summary
Spectral Medical Inc. (TSX: EDT) recently shared a significant update regarding its Tigris trial, a pivotal Phase 3 study assessing the efficacy of Polymyxin B Hemoperfusion (PMX) in treating endotoxemia and septic shock. As of December 2024, the trial has successfully enrolled a total of 140 patients, marking a notable increase in enrollment compared to previous years—59 patients registered in 2024 versus 31 in 2023.
The company attributes this surge in enrollment to the gradual resolution of issues related to the supply of critical intravenous fluids, which had previously impacted recruitment efforts. Dr. John Kellum, Chief Medical Officer of Spectral, expressed optimism about future enrollment, hinting at a potential return to more stable rates as supply chain issues diminish. Chris Seto, the CEO, echoed this sentiment, noting that 2024 saw robust enrollment despite challenges, and anticipates reaching full enrollment by the end of the first quarter of 2025.
Spectral is focused on securing U.S. FDA approval for PMX, a device designed to eliminate endotoxins from the bloodstream, accompanied by the Endotoxin Activity Assay (EAA™), the only FDA-cleared diagnostic for sepsis risk. PMX is already approved for use in Japan and Europe, having been applied in over 340,000 patients worldwide. The Tigris trial aims to validate PMX's benefits in combination with standard care compared to standard care alone, employing a 2:1 randomized method with a projected 150 patients participating.
As Spectral continues its clinical development, the company remains vigilant about various risks and uncertainties, including capital funding and clinical trial site recruitment, all vital to its ongoing research and development efforts. For more information, visit Spectral's official site.
MWN-AI** Analysis
Spectral Medical Inc. (TSX: EDT) is poised for significant developments as it progresses through the Tigris trial, evaluating its Polymyxin B Hemoperfusion (PMX) as a treatment for septic shock. The enrollment of 140 patients, especially the robust increase in participants in 2024, has positioned the company favorably as they aim to complete enrollment by the end of Q1 2025. The easing of production issues for critical intravenous fluids, partly caused by Hurricane Helene, signals a favorable trend in trial continuity and patient recruitment, which had previously been a concern.
From a market perspective, investors should note the potential impact of successful enrollment and eventual trial outcomes on Spectral's stock price and overall market confidence. With PMX already approved in Japan and Europe, and its Breakthrough Device Designation granted by the U.S. FDA, there is a clear pathway for market entry if the trial is successful. Moreover, the growing incidence of septic shock in North America represents a significant market opportunity, with approximately 330,000 new cases annually.
The leadership's optimistic tone regarding enrollment continuity indicates strong momentum, which could translate into positive price movements for EDT upon completion of the trial. However, investors are advised to remain mindful of associated risks, including the company’s ability to secure capital for ongoing trials, potential delays in regulatory approvals, and the competitive landscape in the biomedical sector.
In conclusion, while there are inherent risks tied to the healthcare and pharmaceutical sectors, the developments surrounding the Tigris trial and PMX's existing accolades present a compelling investment opportunity. Investors should keep an eye on trial updates and market performance leading up to Q1 2025.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
• 140 patients enrolled
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
Tigris Enrollment:
- Strong close to 2024 enrollment with 140 patients enrolled at end of December 2024
- 59 patients enrolled in 2024 vs. 31 patients enrolled in 2023
- Experienced improved enrollment in December as issues related to the production of critical intravenous fluids started to ease
- For more information on Hurricane Helene’s impact on the supply of critical intravenous fluids, see the following link: Letter to Health Care Leaders and Stakeholders on Impacts of Hurricane Helene from Secretary Becerra | HHS.gov
Dr. John Kellum, Chief Medical Officer of Spectral, stated, “We view December as a transitional month from an enrollment perspective, as the medical supply chain issues eased. Given the continued strong engagement and enthusiasm at our Tigris sites, we anticipate a return to a more normalized enrollment rate in the new year.”
“Our enrollment throughout 2024 was incredibly robust – even when taking into account the enrollment disruptions encountered throughout the fourth quarter,” said Chris Seto, Chief Executive Officer of Spectral Medical. “We are very much in the final stretch of Tigris enrollment, and project full enrollment closer to the end of the first quarter of 2025.”
About Spectral
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.
The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis https://www.youtube.com/watch?v=6RANrHHi9L8 .
The trial methods are detailed in “ Bayesian methods: a potential path forward for sepsis trials ”.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com .
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company’s ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter’s commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
For further information, please contact:
| Ali Mahdavi | Chris Seto | |
| Capital Markets & Investor Relations | CEO | |
| Spinnaker Capital Markets Inc. | Spectral Medical Inc. | |
| 416-962-3300 | ||
| am@spinnakercmi.com | cseto@spectraldx.com |
FAQ**
What specific strategies does Spectral Medical Inc. EDT:CC plan to implement to ensure a smooth completion of the enrollment phase in the Tigris trial by the end of Q1 2025?
How has the recent improvement in supply chain issues impacted the enrollment rates for the Tigris trial despite the earlier disruptions in 20for Spectral Medical Inc. EDT:CC?
What are Spectral Medical Inc. EDT:CC's expectations regarding the effectiveness of PMX in treating endotoxic septic shock as they finalize patient enrollment for the Tigris trial?
Can you elaborate on the anticipated timeline for obtaining FDA approval for PMX following the completion of the Tigris trial at Spectral Medical Inc. EDT:CC?
**MWN-AI FAQ is based on asking OpenAI questions about Spectral Medical Inc. (TSXC: EDT:CC).
NASDAQ: EDT:CC
EDT:CC Trading
-5.66% G/L:
$0.50 Last:
84,026 Volume:
$0.53 Open:
